Vanguard Total Stock Market ETF (VTI) Daily Snapshot—1/13/25
TipRanks (Tue, 13-Jan 8:23 AM ET)
BioAtla Creates Super-Voting Share to Advance Reverse Split
TipRanks (Mon, 12-Jan 5:06 PM ET)
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—1/12/25
TipRanks (Mon, 12-Jan 7:29 AM ET)
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—1/9/25
TipRanks (Fri, 9-Jan 9:37 AM ET)
Vanguard Total Stock Market ETF (VTI) Daily Snapshot—1/8/25
TipRanks (Thu, 8-Jan 7:56 AM ET)
Globe Newswire (Wed, 31-Dec 7:00 AM ET)
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing
Globe Newswire (Fri, 21-Nov 12:25 AM ET)
BioAtla Achieves Key FDA Milestones and Strategic Progress Amid Cost Discipline in Q3 2025
Market Chameleon (Fri, 14-Nov 6:09 AM ET)
BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
Globe Newswire (Thu, 13-Nov 4:05 PM ET)
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
Bioatla trades on the NASDAQ stock market under the symbol BCAB.
As of January 13, 2026, BCAB stock price declined to $0.31 with 4,332,914 million shares trading.
BCAB has a beta of 1.81, meaning it tends to be more sensitive to market movements. BCAB has a correlation of 0.08 to the broad based SPY ETF.
BCAB has a market cap of $18.12 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, BCAB traded as high as $4.38 and as low as $.24.
The top ETF exchange traded funds that BCAB belongs to (by Net Assets): VTI, VXF.
BCAB has underperformed the market in the last year with a price return of -42.0% while the SPY ETF gained +20.8%. BCAB has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -64.5% and -60.7%, respectively, while the SPY returned +6.5% and +0.9%, respectively.
BCAB support price is $.28 and resistance is $.35 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BCAB shares will trade within this expected range on the day.
